Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 15/20 | 0.50 |
| ▸ | NCF1 | P14598 | 5/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | NCK1 | P16333 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843118 | 0.83 | BACE1 (0.50) | BACE1NCF1NOS2NCK1PLAU | |
| SCHEMBL865202 | 0.78 | CRHBP (0.32) | — | |
| SCHEMBL295035 | 0.76 | CYP1A2 (0.54) | — | |
| SCHEMBL5201973 | 0.74 | — | — | |
| SCHEMBL2478096 | 0.74 | — | — | |
| SCHEMBL4471415 | 0.74 | — | — | |
| SCHEMBL4679303 | 0.74 | — | — | |
| SCHEMBL5748267 | 0.74 | MEN1 (0.59) | PLAU | |
| SCHEMBL3922658 | 0.71 | PIM1 (0.41) | — | |
| SCHEMBL1694903 | 0.71 | CLK1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140336169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2014-11-13 | — | — | US | claimed |
| US-8748607-B2 | Imidazopyrizine syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2014-06-10 | — | — | US | claimed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-20130237521-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| US-8455493-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-06-04 | — | — | US | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-9796718-B2 | 6-(benzo[d]thiazol-5-yl)-n-(3,4-dimethoxyphenyl)imidazo[1,2-a]pyrazin-8-amine | GILEAD CONNECTICUT, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3123864-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2716157-B1 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9212191-B2 | 6-(2,3-dihydro-1H-pyrido-[2,3-b][1,4]oxazin-7-yl)-N-(4-morpholinophenyl)imidazo[1,2-a] pyrazin-8-amine as a spleen tyrosine kinase inhibitor | GILEAD CONNECTICUT, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | disclosed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| US-7084156-B2 | 2-Aminoquinoline compounds | MERCK & CO., INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MERCK SHARP & DOHME CORP. | 2005-02-03 | — | — | US | disclosed |
| EP-1450801-A2 | 2-AMINOQUINOLINE COMPOUNDS | Merck & Co., Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003045313-A2 | 2-AMINOQUINOLINE COMPOUNDS | MERCK & CO. INC. (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031894-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | BACE1 2844/4885NCF1 608/4885NOS2 636/4885 |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | BACE1 2844/4885NCF1 608/4885NOS2 636/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | BACE1 2844/4885NCF1 608/4885NOS2 636/4885 |
| US-20050026915-A1 | 2-Aminoquinoline compounds | MCHR1, MCHR2, MC5R | BACE1 1078/4885NCF1 4069/4885NOS2 2280/4885 |
| US-20140336169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | BACE1 2844/4885NCF1 608/4885NOS2 636/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | BACE1 2844/4885NCF1 608/4885NOS2 636/4885 |
| US-20130237521-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | BACE1 2825/4885NCF1 678/4885NOS2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.